ArticleDiscover oncology2026
LCAT exhibits subtype specific prognostic and immunometabolic associations in renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe three major renal cell carcinoma subtypes-chromophobe renal cell carcinoma (KICH), clear cell renal cell carcinoma (KIRC), and papillary renal cell carcinoma (KIRP)-show marked differences in molecular programs and tumor microenvironmental features, supporting the need for subtype-resolved evaluation of candidate metabolic biomarkers.
methodsUsing TCGA-based transcriptomic and clinical data, we evaluated LCAT expression and its associations with overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS). We further assessed LCAT copy-number variation (CNV), DNA methylation, DNA methyltransferase correlations, m6A-related regulators, and relationships with the tumor immune microenvironment and functional pathways using established public platforms.
resultsLCAT expression was decreased in KICH but increased in KIRC and KIRP relative to normal kidney tissues. Kaplan-Meier analyses showed that low LCAT was associated with shorter OS/DSS/PFS in KICH, whereas high LCAT was associated with shorter OS/DSS/PFS in KIRC; in KIRP, higher LCAT was associated with improved DSS but not OS/PFS. Immune analyses revealed subtype-specific changes in ESTIMATE-derived scores, immune-cell enrichment, and immune-related signatures, with significantly lower StromalScore and ESTIMATEScore in the LCAT-high group in KIRP and altered immune-cell subsets across all three subtypes. LCAT correlated with multiple immunomodulators and MHC molecules. LCAT expression was not correlated with tumor mutational burden (TMB) in any subtype, and MSI showed a significant positive association with LCAT only in KICH. CNV analyses demonstrated a positive CNV-mRNA correlation (most pronounced in KIRP); CNV deletions were consistently associated with the poorest survival in KICH and KIRP, whereas CNV status was not prognostically significant in KIRC. DNA methylation was inversely associated with LCAT expression in KIRC, and higher methylation predicted worse OS only in KICH. LCAT expression was positively correlated with multiple m6A regulators in KIRC and KIRP but not in KICH.
conclusionLCAT displays subtype-dependent prognostic and immunometabolic associations in RCC and may serve as a candidate biomarker for stratification; further external-cohort and experimental validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.